LivaNova PLC (NASDAQ:LIVN) Holdings Boosted by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 286.4% in the 3rd quarter, Holdings Channel reports. The firm owned 207,248 shares of the company’s stock after acquiring an additional 153,611 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in LivaNova were worth $10,889,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Primecap Management Co. CA grew its stake in LivaNova by 0.7% during the 2nd quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock worth $327,889,000 after buying an additional 44,049 shares during the last quarter. Vanguard Group Inc. grew its position in shares of LivaNova by 3.5% during the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock worth $102,537,000 after acquiring an additional 62,480 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of LivaNova by 204.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock worth $70,479,000 after acquiring an additional 863,157 shares during the period. Victory Capital Management Inc. lifted its position in LivaNova by 16.6% in the 3rd quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock valued at $49,130,000 after purchasing an additional 133,401 shares during the last quarter. Finally, Magnetar Financial LLC boosted its stake in LivaNova by 8.1% during the 2nd quarter. Magnetar Financial LLC now owns 814,452 shares of the company’s stock valued at $44,648,000 after purchasing an additional 61,114 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on LIVN. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Robert W. Baird lifted their target price on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of LivaNova in a report on Monday, November 25th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, LivaNova has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Price Performance

NASDAQ:LIVN opened at $52.29 on Tuesday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The business’s 50-day moving average price is $52.29 and its 200 day moving average price is $52.03. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47. The firm has a market cap of $2.84 billion, a P/E ratio of 124.50 and a beta of 1.01.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.